324 related articles for article (PubMed ID: 31088326)
21. The use of fecal calprotectin in monitoring activity of inflammatory bowel diseases.
Knyazev OV; Kagramanova AV; Korneeva IA; Noskova KK; Belousov SV; Parfenov AI
Ter Arkh; 2019 May; 91(4):53-61. PubMed ID: 31094477
[TBL] [Abstract][Full Text] [Related]
22. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
[TBL] [Abstract][Full Text] [Related]
23. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
Sydora MJ; Sydora BC; Fedorak RN
J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
[TBL] [Abstract][Full Text] [Related]
24. Fecal markers: calprotectin and lactoferrin.
Abraham BP; Kane S
Gastroenterol Clin North Am; 2012 Jun; 41(2):483-95. PubMed ID: 22500530
[TBL] [Abstract][Full Text] [Related]
25. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
[TBL] [Abstract][Full Text] [Related]
26. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases.
Diamanti A; Colistro F; Basso MS; Papadatou B; Francalanci P; Bracci F; Muraca M; Knafelz D; De Angelis P; Castro M
Inflamm Bowel Dis; 2008 Sep; 14(9):1229-35. PubMed ID: 18398894
[TBL] [Abstract][Full Text] [Related]
27. The use of fecal calprotectin and lactoferrin in patients with IBD. Review.
Stragier E; Van Assche G
Acta Gastroenterol Belg; 2013 Sep; 76(3):322-8. PubMed ID: 24261027
[TBL] [Abstract][Full Text] [Related]
28. Faecal calprotectin -- a useful tool in the management of inflammatory bowel disease.
Burri E; Beglinger C
Swiss Med Wkly; 2012; 142():w13557. PubMed ID: 22481443
[TBL] [Abstract][Full Text] [Related]
29. Faecal calprotectin: a marker of inflammation throughout the intestinal tract.
Summerton CB; Longlands MG; Wiener K; Shreeve DR
Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):841-5. PubMed ID: 12172403
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome.
Otten CM; Kok L; Witteman BJ; Baumgarten R; Kampman E; Moons KG; de Wit NJ
Clin Chem Lab Med; 2008; 46(9):1275-80. PubMed ID: 18597588
[TBL] [Abstract][Full Text] [Related]
31. Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations.
Laserna-Mendieta EJ; Lucendo AJ
Clin Chem Lab Med; 2019 Aug; 57(9):1295-1307. PubMed ID: 30785706
[TBL] [Abstract][Full Text] [Related]
32. Faecal calprotectin in the diagnosis of inflammatory bowel disease.
Burri E; Beglinger C
Biochem Med (Zagreb); 2011; 21(3):245-53. PubMed ID: 22420238
[TBL] [Abstract][Full Text] [Related]
33. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
Zhulina Y; Cao Y; Amcoff K; Carlson M; Tysk C; Halfvarson J
Aliment Pharmacol Ther; 2016 Sep; 44(5):495-504. PubMed ID: 27402063
[TBL] [Abstract][Full Text] [Related]
34. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders.
Caviglia GP; Pantaleoni S; Touscoz GA; Adriani A; Rosso C; Smedile A; Pellicano R; Astegiano M; Bresso F
Scand J Gastroenterol; 2014 Dec; 49(12):1419-24. PubMed ID: 25369978
[TBL] [Abstract][Full Text] [Related]
35. Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.
Huang VW; Prosser C; Kroeker KI; Wang H; Shalapay C; Dhami N; Fedorak DK; Halloran B; Dieleman LA; Goodman KJ; Fedorak RN
Inflamm Bowel Dis; 2015 Jun; 21(6):1359-67. PubMed ID: 25989340
[TBL] [Abstract][Full Text] [Related]
36. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease.
Walkiewicz D; Werlin SL; Fish D; Scanlon M; Hanaway P; Kugathasan S
Inflamm Bowel Dis; 2008 May; 14(5):669-73. PubMed ID: 18240279
[TBL] [Abstract][Full Text] [Related]
37. Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease.
Kolho KL; Sipponen T; Valtonen E; Savilahti E
Int J Colorectal Dis; 2014 Jan; 29(1):43-50. PubMed ID: 24077667
[TBL] [Abstract][Full Text] [Related]
38. Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.
Ikhtaire S; Shajib MS; Reinisch W; Khan WI
J Gastroenterol; 2016 May; 51(5):434-46. PubMed ID: 26897740
[TBL] [Abstract][Full Text] [Related]
39. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
Klingberg E; Strid H; Ståhl A; Deminger A; Carlsten H; Öhman L; Forsblad-d'Elia H
Arthritis Res Ther; 2017 Feb; 19(1):21. PubMed ID: 28148281
[TBL] [Abstract][Full Text] [Related]
40. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease.
Bunn SK; Bisset WM; Main MJ; Gray ES; Olson S; Golden BE
J Pediatr Gastroenterol Nutr; 2001 Jul; 33(1):14-22. PubMed ID: 11479402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
